CD19, a B-cell surface protein ... and several non-Hodgkin lymphomas. This universal expression and specificity for a single cell lineage have rendered CD19 an appealing target for antibody ...

we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal ...

It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell ... detect the anti-CD19 CAR expression on the surface of transduced T cells. These proteins have been ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...